

JANUARY 2026

Date	Headline and Source	Link	Summary
5 th January	Pharma trends that will shape 2026: Building a future-ready, patient centric industry Express Pharma, January 05, 2026	Pharma trends that will shape 2026: Building a future-ready, patient centric industry	The article explores how the pharmaceutical industry is being reshaped as it approaches 2026, driven by digital transformation, scientific innovation, and a stronger focus on patient-centric care
6 th January	Pre-Budget Expectations: GST Simplifications Key to Pharma and Life Sciences Growth Biospectrum, January 06, 2026	Pre-Budget Expectations: GST Simplifications Key to Pharma and Life Sciences Growth	The story features a quote from Mr. Anil Matai, along with perspectives from other industry leaders, including Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; B.G. Barve, Chairperson, Taxation Committee, IDMA and Joint Managing Director, Blue Cross Laboratories and Dr. Ranjeet Mehta, CEO and Secretary General, PHD Chamber of Commerce and Industry.
10 th January	Ahead of union budget, pharma industry seeks R&D boost, GST rationalisation Express Pharma, January 10, 2026	Ahead of union budget, pharma industry seeks R&D boost, GST rationalisation	Anil Matai, Director General, OPPI: As India approaches the upcoming Union Budget, OPPI believes that there is an opportunity to further strengthen the country's healthcare and life sciences ecosystem with a clear patient first focus. Sustained policy support over the past few years has laid a strong foundation for innovation, regulatory reforms, and improved access.
12 th January	Deal St: Cognizant inks over \$1bn contract with Novartis The Times of India, January 12, 2026	Deal St: Cognizant inks over \$1bn contract with Novartis	Cognizant is learnt to have secured a deal worth over \$1 billion from Swiss pharma major Novartis as part of a consolidation contract that includes renewals as well as new scope spanning application services, infrastructure, data and AI-led offerings, people in the know told TOI.
12 th January	Ozempic launched in India, prices start at Rs 8,800 per month The Financial Express, January 12, 2026	Ozempic launched in India, prices start at Rs 8,800 per month	Danish drugmaker Novo Nordisk has launched its popular weight loss drug Ozempic in India, with its lowest dose of 0.25 mg priced at Rs 2,200 per week or Rs 8,800 per month, reported Reuters. Ozempic prices in India unveiled.
13 th January	Pharma industry seeks R&D sops, simplification of regulatory framework in Budget PTI News, January 13, 2026	Pharma industry seeks R&D sops, simplification of regulatory framework in Budget	" The Organisation of Pharmaceutical Producers of India (OPPI), which represents research-based global pharmaceutical companies in India, stated that there is an opportunity in the upcoming Budget to further strengthen the country's healthcare and life sciences ecosystem with a clear patientfirst focus.

13 th January	Pharma industry seeks R D sops simplification of regulatory framework in Budget The Week, January 13, 2026	Pharma industry seeks R D sops simplification of regulatory framework in Budget	The Organisation of Pharmaceutical Producers of India (OPPI), which represents research-based global pharmaceutical companies in India, stated that there is an opportunity in the upcoming Budget to further strengthen the country's healthcare and life sciences ecosystem with a clear patientfirst focus.
13 th January	CDSCO Panel Backs Label Change Allowing Endocrinologists, Rheumatologists to Prescribe Amgen's Romosozumab Medical Dialogues, January 13, 2026	CDSCO Panel Backs Label Change Allowing Endocrinologists, Rheumatologists to Prescribe Amgen's Romosozumab	Romosozumab Injection 90 mg/mL is approved in India for the treatment of osteoporosis in postmenopausal women at high risk of fracture. The firm placed a proposal before the committee seeking modification of the existing warning statement mentioned on the approved label of the drug.
14 th January	Pharma industry seeks R&D sops, simplification of regulatory framework in Budget India Shipping News, January 14, 2026	Pharma industry seeks R&D sops, simplification of regulatory framework in Budget	The Organisation of Pharmaceutical Producers of India (OPPI), which represents research-based global pharmaceutical companies in India, stated that there is an opportunity in the upcoming Budget to further strengthen the country s healthcare and life sciences ecosystem with a clear patientfirst focus.
16 th January	Pharma trends that will shape 2026: Building a future ready, patientcentric industry Express Pharma, January 16, 2026	Pharma trends that will shape 2026: Building a future ready, patientcentric industry	Anil Matai, Director General, OPPI, outlines the major pharmaceutical trends expected to shape 2026, detailing how digital health, AI-driven drug development, precision medicine and resilient supply chains will influence the industry's shift towards a future-ready, patient-centric ecosystem.
16 th January	Johnson and Johnson Gets CDSCO Panel Nod for Talquetamab in Relapsed Multiple Myeloma, Phase IV Trial Mandated Medical Dialogues, January 16, 2026	Johnson and Johnson Gets CDSCO Panel Nod for Talquetamab in Relapsed Multiple Myeloma, Phase IV Trial Mandated	The decision follows earlier SEC recommendations dated 21.05.2025, after which the firm submitted additional justification addressing the unmet medical need in India, along with efficacy results from extended global clinical trials.
20 th January	Syngene expands research collaboration with Bristol Myers Squibb The Economic Times, January 20, 2026	Syngene expands research collaboration with Bristol Myers Squibb	The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene s first dedicated R&D Center, which was fully commissioned in 2009.
21 st January	Breast Cancer Deaths in India Remain Alarmingly High; Novartis Take Charge Aims to Change That Times Now News, January 21, 2026	Breast Cancer Deaths in India Remain Alarmingly High; Novartis Take Charge Aims to Change That	Breast cancer remains a major public health challenge in India, with one woman dying every eight minutes due to late diagnosis and low awareness. To address this, Novartis, a Swiss-based pharmaceutical giant, has launched the Take Charge

			campaign in collaboration with Times Network, aiming to promote early detection, informed decision-making, caregiver support, and patient-centered breast cancer care. Read on to know more about it.
21 st January	Danish Novo Holdings Acquires 49% Stake in Pune's Surya Hospitals Outlook Business, January 21, 2026	Danish Novo Holdings Acquires 49% Stake in Pune's Surya Hospitals	Surya Hospitals has built an exceptional reputation over decades for excellence in women s and children's care, underpinned by outstanding doctors and strong clinical outcomes We are pleased to partner with Surya as a long-term investor and support its ambition to broaden access to high-quality maternal and paediatric care, said Amit Kakar, Managing Partner and Head of Asia at Novo Holdings.
21 st January	CDSCO approves highest number of new drugs with rDNA origin for import & manufacture in 2025 PharmaBiz, January 21, 2026	CDSCO approves highest number of new drugs with rDNA origin for import & manufacture in 2025	The drugs approved for import and marketing in 2025 include eculizumab, datopotamab deruxtecan, and approval of additional indication for durvalumab, trastuzumab deruxtecan and benralizumab for AstraZeneca Pharma, Insulin Icodec, concizumab, semaglutide injection, and approval for additional indication for semaglutide injection for Novo Nordisk, antihemophilic factor (recombinant factor VIII) I.P. 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU vial for Bayer Pharmaceuticals, FDC of nivolumab and relatlimab, and approval of additional indication for luspatercept, nivolumab, Ipilimumab for BristolMeyer Squibb India.
23 rd January	Novavax signs licensing agreement with Pfizer for vaccine development The Economic Times, January 23, 2026	Novavax signs licensing agreement with Pfizer for vaccine development	Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, and the smaller company s shares jumped nearly 7% Pfizer will gain access to Novavax's MatrixM adjuvant through the nonexclusive deal
23 rd January	Viyash Scientific Forms Strategic Partnership with Boehringer Ingelheim for Companion Animal Products in India Scanx Trade, January 23, 2026	Viyash Scientific Forms Strategic Partnership with Boehringer Ingelheim for Companion Animal Products in India	Viyash Scientific has entered into a strategic partnership with Boehringer Ingelheim, a global pharmaceutical company, to expand companion animal products in the Indian market. This collaboration marks a significant business development for the company as it seeks to strengthen its position in the veterinary healthcare sector.
23 rd January	Merck unit partners with global health coalition to develop affordable Ebola vaccine	Merck unit partners with global health coalition to develop affordable Ebola vaccine	Merck & Co unit MSD and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have partnered on a \$30 million program to develop an updated

	The Economic Times, January 23, 2026		version of the drugmaker s Ebola vaccine aimed at improving affordability and access for low and middleincome countries.
25 th January	India-EU FTA may lower costs of novel drugs for Indian patients, medical equipment Live Mint, January 28, 2026	India-EU FTA may lower costs of novel drugs for Indian patients, medical equipment	“While OPPI is awaiting the release of the full Agreement, it has gone through Memo on EU-India Free Trade Agreement Chapter by Chapter Summary released by the European Commission and is encouraged that the summary states that the FTA provides a high level of protection and enforcement of IP (intellectual property) rights, in line with Indian and EU IP laws and also covers protection of trade secrets and undisclosed information," Anil Matai, director general of the Organisation of Pharmaceutical Producers of India (OPPI), which represents research-based global pharmaceutical companies in India, said in a statement.
